Citations

Showing 10 of 108094 citations.

International Consensus Classification for myeloid neoplasms at‐a‐glance
Hasserjian, Robert P. , Cazzola, Mario , Tefferi, Ayalew , Arber, Daniel A. , Tefferi, Ayalew , Arber, Daniel A , Cazzola, Mario , Orazi, Attilio , Döhner, Hartmut

Mayo Clinic

American Journal of Hematology | October 31, 2022 | Volume: 98 | Issue: 1 | Pages: 6-10

10.1002/ajh.26772 | PMID 36314608 Get It

Esophageal Apoplexy
Myburgh, Sarel J., Fidler, Jeff L., Lapp, R , Katzka, David A. , Myburgh, Sarel, Lapp, Robert T, Fidler, Jeff L.

Mayo Clinic

ACG Case Reports Journal | October 31, 2022 | Volume: 9 | Issue: 10 | Pages: e00769

10.14309/crj.0000000000000769 | PMID 36277741 Get It

Where Have All the Diagnostic Morphological Parasitologists Gone?
Bradbury, Richard S. , Potters, Idzi , Mathison, Blaine A. , Mewara, Abhishek , Tamarozzi, Francesca , Couturier, Marc Roger , Pritt, Bobbi S. , Potters, Idzi , Mathison, Blaine A , Pritt, Bobbi S , Sapp, Sarah G. H. , Frean, John , Sheorey, Harsha , Chiodini, Peter L.

Mayo Clinic

Journal of Clinical Microbiology | October 31, 2022 | Volume: 60 | Issue: 11 | Pages: No page available

10.1128/jcm.00986-22 | PMID 36314793 Get It

Advances in laboratory techniques have revolutionized parasitology diagnostics over the past several decades. Widespread implementation of rapid antigen detection tests has greatly expanded access to tests for global parasitic threats such as malaria, while next-generation amplification and sequencing methods allow for sensitive and specific detection of human and animal parasites in complex specimen matrices.
Clinical Outcomes of COVID-19 Treated with Remdesivir Across the Continuum of Care
Rivera, Christina G. , Chesdachai, Supavit , Draper, Evan , Arndt, Richard A., Chesdachai, Supavit , Rivera, Christina G , Arndt, Richard, Mara, Kristin C. , Suarez, Maria Lourdes Gonzalez , Razonable, Raymund R.

Mayo Clinic

No container title available | October 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166720862.27650559/v1 Get It

Introduction: During the early phase of the coronavirus disease 2019 (COVID-19), remdesivir was only approved for hospitalized patients. Our institution developed hospital-based, outpatient infusion centers for selected hospitalized patients with COVID-19 who had clinical improvement to allow for early dismissal. The outcomes of patients who transitioned to complete remdesivir in the outpatient setting were examined. Methods: Retrospective study of all hospitalized adult patients with COVID-19 who received at least one dose of remdesivir from 11/6/2020 to 11/5/2021 at one of the Mayo Clinic hospitals. Results: Among 3,029 hospitalized patients who received treatment with remdesivir for COVID-19, the majority (89.5%) completed the recommended the five-day course. Among them, 2,169 (80%) completed treatment during hospitalization, while 542 (20.0%) patients were dismissed to complete remdesivir in outpatient infusion centers. Patients who completed the treatment in the outpatient setting had lower odds of death within 28 days (aOR 0.14, 95% CI 0.06-0.32, p<0.001). However, their rate of subsequent hospital encounters within 30 days was higher (aHR 1.88, 95% CI 1.27-2.79, p=0.002). Among patients treated with remdesivir only in the inpatient setting, the adjusted odds of death within 28 days were significantly higher among those who did not complete the 5-day course of remdesivir (aOR 2.07, 95% CI 1.45-2.95, p<0.001). Conclusions: This study describes the clinical outcomes of a strategy of transitioning remdesivir therapy from inpatient to outpatient among selected patients. Mortality was lower among patients who completed the 5-day course of remdesivir.
Nocardia farcinica pituitary abscess in an immunocompetent patient: illustrative case
Scheitler, Kristen M. , Graffeo, Christopher S. , Meyer, Fredric B. , Carlstrom, Lucas P. , Bauman, Megan M. J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | October 31, 2022 | Volume: 4 | Issue: 18 | Pages: No page available

10.3171/case22266 | PMID 36317239 Get It

BACKGROUND Pituitary abscess is a rare clinical entity, typically precipitated by Staphylococcus , Pseudomonas , or Aspergillus infection. Although Nocardia species–associated central nervous system abscesses have been documented in immunocompromised patients, no case of Nocardia pituitary abscesses has been previously reported. OBSERVATIONS A 44-year-old man presented with hemoptysis and was found to have a cavitary right lung nodule, which was presumed histoplasmosis, prompting antifungal treatment. Several months later, he developed panhypopituitarism. Magnetic resonance imaging identified a pituitary mass, which subsequently underwent transsphenoidal endoscopic biopsy. Infectious workup was negative, and the patient was discharged on intravenous ertapenem therapy. Over several months, he developed progressive headaches, and updated imaging confirmed interval enlargement of the mass with new cavernous sinus invasion. He underwent repeat endoscopic biopsy, which yielded positive cultures for Nocardia farcinica and prompted successful treatment with trimethoprim-sulfamethoxazole and linezolid. LESSONS The current study highlights a previously unreported clinical entity, the first pituitary abscess attributable to Nocardia sp. or N. farcinica, which arose in a young, immunocompetent individual. Although rare, atypical infections represent an important component in the differential diagnosis for sellar mass lesions.
Orthopaedic Shoulder and Elbow Fellowship Directors in the United States Have Substantial Research Output but Lack Diversity
Smith, Jacob F. , Elahi, Muhammad Ali , Doan, Matthew K. , Pollock, Jordan R. , Hassebrock, Jeffrey D. , Makovicka, Justin L. , Brinkman, Joseph C. , Patel, Karan A. , Patel, Karan , Pollock, Jordan Riley , Hassebrock, Jeffrey D , Moore, M. Lane

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | October 31, 2022 | Volume: 4 | Issue: 6 | Pages: No page available

10.1016/j.asmr.2022.08.011 | PMID 36579054 Get It

Purpose To investigate the characteristics of shoulder and elbow fellowship directors (FDs). Methods FDs for shoulder and elbow fellowship programs in the United States were identified. Demographic, educational, and professional background data were collected from available curricula vitarum, institutional biographies, and the Scopus database. Data collected included age, sex, race/ethnicity, training locations, graduation years, advanced degrees, current institutional information, and personal research H‐index. Results Thirty current orthopaedic shoulder and elbow FDs were identified. The mean Scopus H‐index was 25.5. The mean age of FDs was 52.1 years. In total, 29 FDs (96.7%) were male and 1 (3.3%) was female. In addition, 25 of the 30 (83.3%) were White (83.3%), 4 were Asian, and 1 (3.3%) was Hispanic. Two (6.7%) had a military affiliation. Mean time from fellowship training graduation to FD appointment was 13.5 years. Mean number of years as FD was 6.1 years, whereas the number of years tenure with an FD‐affiliated institution was 13.0 years. Mean calendar years for completion of orthopaedic residency training and fellowship training were 1998 and 2000, respectively. The residencies that produced the most future FDs were Hospital of the University of Pennsylvania (n = 2) and University of Nebraska Medical Center/Creighton University Health Foundation (n = 2). The fellowship that produced the most future FDs was Columbia University (n = 6). Moderate correlation was found between age and Scopus H‐index (r = 0.48; P = .04) and years as FD and Scopus H‐index (r = 0.42; P = .03). Conclusions Women and minorities are under‐represented in leadership positions in shoulder and elbow surgery. Shoulder and elbow FDs have the highest H‐index of any subspecialty reported in the orthopaedic literature. Research productivity is an important qualification when considering the characteristics of shoulder and elbow FDs. Clinical Relevance Fellowship directors can have a profound influence on current and future orthopaedic surgeons. It is important to identify the traits that characterize current fellowship directors to have a better understanding of who we choose as leaders in our field.
Performance Is Regained Within 2 Seasons After Quadriceps Tendon Tears in National Basketball Association Players
Morikawa, Landon , Tummala, Sailesh V. , Brinkman, Joseph C. , Chhabra, Anikar , Chhabra, Anikar , Tummala, Sailesh V

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | October 31, 2022 | Volume: 4 | Issue: 6 | Pages: No page available

10.1016/j.asmr.2022.09.009 | PMID 36579031 Get It

Purpose To characterize quadriceps tendon injuries over 30 National Basketball Association (NBA) seasons and assess the effects on player performance upon return to play. Methods Partial and complete quadriceps tendon tears in NBA players between the 1990‐1991 and 2021‐2022 seasons were queried from a publicly available database. The primary outcomes were changes in player performance statistics obtained from each player’s preindex season and first 2 postindex seasons. These interseason changes were compared with the changes of a healthy control cohort. Each injured player was matched with 2 controls using position, career length and win shares by season. The secondary measure of this study was the rate of return to play. Results Nine quadriceps tendon tears (6 partial, 3 complete) were identified in NBA players. Seven (78%) of the players returned to play in NBA games, missing 50 ± 30 games and 214 ± 112 calendar days on average. Comparisons between these player’s preindex and first postindex seasons revealed significant declines in games played (73.2 ± 6.6 vs 41.8 ± 10.8, P = .009) and minutes per game (27.2 ± 2.9 vs 23.0 ± 3.7, P = .042). When compared with controls, only the decrease in games played was significant (–31.3 ± 7.6 vs 1.4 ± 8.2, P = .004). These findings were consistent when comparing preindex and second postindex seasons (games played: 79.6 ± 1.9 vs –28.4 ± 5.4, P = .006; minutes per game: 29.3 ± 2.6 vs 51.2 ± 4.6, P = .003). All other player performance metrics including player efficiency rating returned to near‐baseline levels in the first 2 seasons after injury. Conclusion NBA players with quadriceps tendon tears return to play in 78% of cases. These athletes achieved preinjury levels of performance within 1 to 2 seasons, but with reduced games played per season. Level of Evidence IV, therapeutic case series.
We Asked the Experts: Surgical Approach to Low Rectal Cancer—Where Innovation Happens
Grass, Fabian , Larson, David W.

Mayo Clinic

World Journal of Surgery | October 30, 2022 | Volume: 47 | Issue: 4 | Pages: 1071-1072

10.1007/s00268-022-06823-3 | PMID 36310324 Get It

Proposed risk‐scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
Yang, Pei‐Yu , Chen, Haimin , Liang, Xinyue , Xu, Weiling , Yu, Shanshan , Yi, Xingcheng , Tian, Mengru, Yue, Tingting , Yan, Yurong, Hu, Zhongli, Kumar, Shaji , Zhou, Fan , Dai, Yun , Jin, Fengyan , Kumar, Shaji K , Dai, Yun , Jin, Fengyan , Huang, Wenyang , Guo, Qiang , Yue, Tingting, Li, Mengyao , Zhang, Yingjie , Zhang, Mengxue

Mayo Clinic

American Journal of Hematology | October 30, 2022 | Volume: 98 | Issue: 2 | Pages: 251-263

10.1002/ajh.26774 | PMID 36309982 Get It

Abstract1q gain (+1q) is the most common high‐risk cytogenetic abnormality (HRCA) in patients with multiple myeloma (MM). However, its prognostic value remains unclear in the era of novel agents. Here, we retrospectively analyzed the impact of +1q on the outcomes of 934 patients newly diagnosed with MM. +1q was identified in 53.1% of patients and verified as an independent variate for inferior overall survival (OS) (hazard ratio, 1.400; 95% confidence interval, 1.097–1.787; p = .007). Concurrence of other HRCAs (particularly t(14;16) and del(17p)) further exacerbated the outcomes of patients with +1q, suggesting prognostic heterogeneity. Thus, a risk‐scoring algorithm based on four risk variates (t(14;16), hypercalcemia, ISS III, and high LDH) was developed to estimate the outcomes of patients with +1q. Of the patients, 376 evaluable patients with +1q were re‐stratified into low (31.6%), intermediate (61.7%), and high risk (6.7%) groups, with significantly different progression‐free survival and OS (p < .0001), in association with early relapse of the disease. The prognostic value of this model was validated in the CoMMpass cohort. While attaining undetectable MRD largely circumvented the adverse impact of +1q, it scarcely ameliorated the outcome of the patients with high risk, who likely represent a subset of patients with extremely poor survival. Hence, patients with +1q are a heterogeneous group of high‐risk patients, therefore underlining the necessity for their re‐stratification. The proposed simple risk‐scoring model can estimate the outcomes of patients with +1q, which may help guide risk‐adapted treatment for such patients.
Enhancing inclusivity of older Black and African American adults in mental health research
Auguste, Elizabeth J., McDuffie, Danielle , Ighodaro, Eseosa T. , Moye, Jennifer

Mayo Clinic

Clinical Gerontologist | October 30, 2022 | Volume: 46 | Issue: 1 | Pages: 5-13

10.1080/07317115.2022.2133453 | PMID 36309844 Get It